Why the study?
Pulmonary hemorrhage due to antiplatelet therapy is a rare but life-threatening event, and specific guidelines for managing these patients are lacking.
Proposes a novel management algorithm for patients experiencing rare but life-threatening pulmonary hemorrhage while on antiplatelet therapy.
Alerts clinicians to rare pulmonary hemorrhage on antiplatelet therapy; leaves open optimal management strategies.
Antiplatelet therapy including aspirin and thienopyridine agents (such as clopidogrel, prasugrel and ticagrelor) are often used in patients with coronary disease. Pulmonary hemorrhage due to antiplatelet therapy although very rare, when excessive, is a life-threatening event. So far, there is lack of specific guidelines for the management of these patients. We report a case series of 5 patients receiving antiplatelet therapy who were admitted to the hospital due to pulmonary hemorrhage related to antiplatelet therapy. We also propose an algorithm on the management of these patients taking into consideration the balance between thrombotic and bleeding risk and the severity of the hemorrhage.
No takes yet. Share an insight, caveat, or question.
Tomos et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: